{
  "symbol": "LEXXW",
  "company_name": "Lexaria Bioscience Corp WT",
  "ir_website": "https://lexariabioscience.com/investors/",
  "structured_data": [
    {
      "section_name": "Latest News",
      "links": [
        {
          "title": "Lexaria Bioscience Announces Positive Data from its Phase 1 Study of DehydraTECH-CBD with Aurora Cannabis",
          "url": "https://lexariabioscience.com/investors/press-releases/",
          "content": "Lexaria Bioscience - [![Lexaria Bioscience]( http://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB.png)](https://lexariabioscience.com/ \"Lexaria Bioscience\")\n\nNASDAQ:LEXX; NASDAQ WARRANT:LEXXW \n\n[Contact](https://lexariabioscience.com/contact/)\n\n#  Press Releases\n\n[Lexaria Bioscience](https://lexariabioscience.com \"Go to Lexaria Bioscience.\") → [Investor Relations](https://lexariabioscience.com/investors/ \"Go to Investor Relations.\") → Press Releases\n\n☰\n\n  * [Overview](https://lexariabioscience.com/investors/)\n  * [Press Releases](https://lexariabioscience.com/investors/press-releases/)\n  * [Events & Presentations](https://lexariabioscience.com/investors/events-and-presentations/)\n  * [Company Info](https://lexariabioscience.com/investors/company-information/)\n    * [Overview](https://lexariabioscience.com/investors/company-information/)\n    * [Management Team](https://lexariabioscience.com/investors/management-team/)\n    * [Annual Meeting / Special Meeting](https://lexariabioscience.com/investors/meeting/)\n  * [Analyst Coverage](https://lexariabioscience.com/investors/analyst-coverage/)\n  * [Stock Data](https://lexariabioscience.com/investors/stock-data/)\n  * [Financial Info](https://lexariabioscience.com/investors/financial-information/)\n    * [SEC Filings](https://lexariabioscience.com/investors/sec-filings/)\n    * [Quarterly Reports](https://lexariabioscience.com/investors/quarterly-reports/)\n    * [SEDAR+](https://www.sedarplus.ca/landingpage/)\n  * [Legend Removal](https://lexariabioscience.com/investors/legend-removal/)\n  * [Governance](#)\n    * [Board of Directors](https://lexariabioscience.com/investors/board-of-directors/)\n    * [Governance Documents](https://lexariabioscience.com/investors/governance-documents/)\n    * [Board Committees](https://lexariabioscience.com/investors/board-committees/)\n  * [Resources](#)\n    * [Email Alerts](https://lexariabioscience.com/investors/email-alerts/)\n    * [Investor FAQ](https://lexariabioscience.com/investors/ir-faq/)\n    * [IR Contact](https://lexariabioscience.com/investors/ir-contact/)\n\n\n\n## Press Releases\n\n[](#top)\n"
        },
        {
          "title": "Lexaria Bioscience Files Annual Report for Fiscal Year Ending August 31, 2023",
          "url": "https://lexariabioscience.com/investors/press-releases/",
          "content": "Lexaria Bioscience - [![Lexaria Bioscience]( http://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB.png)](https://lexariabioscience.com/ \"Lexaria Bioscience\")\n\nNASDAQ:LEXX; NASDAQ WARRANT:LEXXW \n\n[Contact](https://lexariabioscience.com/contact/)\n\n#  Press Releases\n\n[Lexaria Bioscience](https://lexariabioscience.com \"Go to Lexaria Bioscience.\") → [Investor Relations](https://lexariabioscience.com/investors/ \"Go to Investor Relations.\") → Press Releases\n\n☰\n\n  * [Overview](https://lexariabioscience.com/investors/)\n  * [Press Releases](https://lexariabioscience.com/investors/press-releases/)\n  * [Events & Presentations](https://lexariabioscience.com/investors/events-and-presentations/)\n  * [Company Info](https://lexariabioscience.com/investors/company-information/)\n    * [Overview](https://lexariabioscience.com/investors/company-information/)\n    * [Management Team](https://lexariabioscience.com/investors/management-team/)\n    * [Annual Meeting / Special Meeting](https://lexariabioscience.com/investors/meeting/)\n  * [Analyst Coverage](https://lexariabioscience.com/investors/analyst-coverage/)\n  * [Stock Data](https://lexariabioscience.com/investors/stock-data/)\n  * [Financial Info](https://lexariabioscience.com/investors/financial-information/)\n    * [SEC Filings](https://lexariabioscience.com/investors/sec-filings/)\n    * [Quarterly Reports](https://lexariabioscience.com/investors/quarterly-reports/)\n    * [SEDAR+](https://www.sedarplus.ca/landingpage/)\n  * [Legend Removal](https://lexariabioscience.com/investors/legend-removal/)\n  * [Governance](#)\n    * [Board of Directors](https://lexariabioscience.com/investors/board-of-directors/)\n    * [Governance Documents](https://lexariabioscience.com/investors/governance-documents/)\n    * [Board Committees](https://lexariabioscience.com/investors/board-committees/)\n  * [Resources](#)\n    * [Email Alerts](https://lexariabioscience.com/investors/email-alerts/)\n    * [Investor FAQ](https://lexariabioscience.com/investors/ir-faq/)\n    * [IR Contact](https://lexariabioscience.com/investors/ir-contact/)\n\n\n\n## Press Releases\n\n[](#top)\n"
        }
      ]
    },
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "Latest Financial Results",
          "url": "https://lexariabioscience.com/investors/financial-information/",
          "content": "Lexaria Bioscience - [![Lexaria Bioscience]( http://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB.png)](https://lexariabioscience.com/ \"Lexaria Bioscience\")\n\nNASDAQ:LEXX; NASDAQ WARRANT:LEXXW \n\n[Contact](https://lexariabioscience.com/contact/)\n\n#  Financial Information\n\n[Lexaria Bioscience](https://lexariabioscience.com \"Go to Lexaria Bioscience.\") → [Investor Relations](https://lexariabioscience.com/investors/ \"Go to Investor Relations.\") → Financial Information\n\n☰\n\n  * [Overview](https://lexariabioscience.com/investors/)\n  * [Press Releases](https://lexariabioscience.com/investors/press-releases/)\n  * [Events & Presentations](https://lexariabioscience.com/investors/events-and-presentations/)\n  * [Company Info](https://lexariabioscience.com/investors/company-information/)\n    * [Overview](https://lexariabioscience.com/investors/company-information/)\n    * [Management Team](https://lexariabioscience.com/investors/management-team/)\n    * [Annual Meeting / Special Meeting](https://lexariabioscience.com/investors/meeting/)\n  * [Analyst Coverage](https://lexariabioscience.com/investors/analyst-coverage/)\n  * [Stock Data](https://lexariabioscience.com/investors/stock-data/)\n  * [Financial Info](https://lexariabioscience.com/investors/financial-information/)\n    * [SEC Filings](https://lexariabioscience.com/investors/sec-filings/)\n    * [Quarterly Reports](https://lexariabioscience.com/investors/quarterly-reports/)\n    * [SEDAR+](https://www.sedarplus.ca/landingpage/)\n  * [Legend Removal](https://lexariabioscience.com/investors/legend-removal/)\n  * [Governance](#)\n    * [Board of Directors](https://lexariabioscience.com/investors/board-of-directors/)\n    * [Governance Documents](https://lexariabioscience.com/investors/governance-documents/)\n    * [Board Committees](https://lexariabioscience.com/investors/board-committees/)\n  * [Resources](#)\n    * [Email Alerts](https://lexariabioscience.com/investors/email-alerts/)\n    * [Investor FAQ](https://lexariabioscience.com/investors/ir-faq/)\n    * [IR Contact](https://lexariabioscience.com/investors/ir-contact/)\n\n\n\n## Financial Information\n\n### Latest Financial Results\n\n### Latest 10-K\n\n### Financials\n\n[Income Statement](https://lexariabioscience.com/investors/financial-info/#income-statement) [Balance Sheet](https://lexariabioscience.com/investors/financial-info/#balance-sheet) [Cash Flow](https://lexariabioscience.com/investors/financial-info/#cash-flow)\n\n[](#top)\n"
        }
      ]
    },
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Lexaria Reports Fiscal Year 2023 Results",
          "url": "https://lexariabioscience.com/investors/press-releases/",
          "content": ""
        },
        {
          "title": "Lexaria Bioscience Provides Update on DehydraTECH Studies",
          "url": "https://lexariabioscience.com/investors/press-releases/",
          "content": ""
        }
      ]
    },
    {
      "section_name": "Events & Presentations",
      "links": [
        {
          "title": "View All Presentations",
          "url": "https://lexariabioscience.com/investors/events-and-presentations/",
          "content": "Lexaria Bioscience - [![Lexaria Bioscience]( http://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB.png)](https://lexariabioscience.com/ \"Lexaria Bioscience\")\n\nNASDAQ:LEXX; NASDAQ WARRANT:LEXXW \n\n[Contact](https://lexariabioscience.com/contact/)\n\n#  Events & Presentations\n\n[Lexaria Bioscience](https://lexariabioscience.com \"Go to Lexaria Bioscience.\") → [Investor Relations](https://lexariabioscience.com/investors/ \"Go to Investor Relations.\") → Events & Presentations\n\n☰\n\n  * [Overview](https://lexariabioscience.com/investors/)\n  * [Press Releases](https://lexariabioscience.com/investors/press-releases/)\n  * [Events & Presentations](https://lexariabioscience.com/investors/events-and-presentations/)\n  * [Company Info](https://lexariabioscience.com/investors/company-information/)\n    * [Overview](https://lexariabioscience.com/investors/company-information/)\n    * [Management Team](https://lexariabioscience.com/investors/management-team/)\n    * [Annual Meeting / Special Meeting](https://lexariabioscience.com/investors/meeting/)\n  * [Analyst Coverage](https://lexariabioscience.com/investors/analyst-coverage/)\n  * [Stock Data](https://lexariabioscience.com/investors/stock-data/)\n  * [Financial Info](https://lexariabioscience.com/investors/financial-information/)\n    * [SEC Filings](https://lexariabioscience.com/investors/sec-filings/)\n    * [Quarterly Reports](https://lexariabioscience.com/investors/quarterly-reports/)\n    * [SEDAR+](https://www.sedarplus.ca/landingpage/)\n  * [Legend Removal](https://lexariabioscience.com/investors/legend-removal/)\n  * [Governance](#)\n    * [Board of Directors](https://lexariabioscience.com/investors/board-of-directors/)\n    * [Governance Documents](https://lexariabioscience.com/investors/governance-documents/)\n    * [Board Committees](https://lexariabioscience.com/investors/board-committees/)\n  * [Resources](#)\n    * [Email Alerts](https://lexariabioscience.com/investors/email-alerts/)\n    * [Investor FAQ](https://lexariabioscience.com/investors/ir-faq/)\n    * [IR Contact](https://lexariabioscience.com/investors/ir-contact/)\n\n\n\n## Events & Presentations\n\n### Upcoming Events\n\n### Past Events\n\n### Presentations\n\n### Fact Sheet\n\n[](#top)\n"
        }
      ]
    },
    {
      "section_name": "Analyst Coverage",
      "links": [
        {
          "title": "Analyst Coverage Overview",
          "url": "https://lexariabioscience.com/investors/analyst-coverage/",
          "content": "Lexaria Bioscience - [![Lexaria Bioscience]( http://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB.png)](https://lexariabioscience.com/ \"Lexaria Bioscience\")\n\nNASDAQ:LEXX; NASDAQ WARRANT:LEXXW \n\n[Contact](https://lexariabioscience.com/contact/)\n\n#  Analyst Coverage\n\n[Lexaria Bioscience](https://lexariabioscience.com \"Go to Lexaria Bioscience.\") → [Investor Relations](https://lexariabioscience.com/investors/ \"Go to Investor Relations.\") → Analyst Coverage\n\n☰\n\n  * [Overview](https://lexariabioscience.com/investors/)\n  * [Press Releases](https://lexariabioscience.com/investors/press-releases/)\n  * [Events & Presentations](https://lexariabioscience.com/investors/events-and-presentations/)\n  * [Company Info](https://lexariabioscience.com/investors/company-information/)\n    * [Overview](https://lexariabioscience.com/investors/company-information/)\n    * [Management Team](https://lexariabioscience.com/investors/management-team/)\n    * [Annual Meeting / Special Meeting](https://lexariabioscience.com/investors/meeting/)\n  * [Analyst Coverage](https://lexariabioscience.com/investors/analyst-coverage/)\n  * [Stock Data](https://lexariabioscience.com/investors/stock-data/)\n  * [Financial Info](https://lexariabioscience.com/investors/financial-information/)\n    * [SEC Filings](https://lexariabioscience.com/investors/sec-filings/)\n    * [Quarterly Reports](https://lexariabioscience.com/investors/quarterly-reports/)\n    * [SEDAR+](https://www.sedarplus.ca/landingpage/)\n  * [Legend Removal](https://lexariabioscience.com/investors/legend-removal/)\n  * [Governance](#)\n    * [Board of Directors](https://lexariabioscience.com/investors/board-of-directors/)\n    * [Governance Documents](https://lexariabioscience.com/investors/governance-documents/)\n    * [Board Committees](https://lexariabioscience.com/investors/board-committees/)\n  * [Resources](#)\n    * [Email Alerts](https://lexariabioscience.com/investors/email-alerts/)\n    * [Investor FAQ](https://lexariabioscience.com/investors/ir-faq/)\n    * [IR Contact](https://lexariabioscience.com/investors/ir-contact/)\n\n\n\n## Analyst Coverage\n\n[](#top)\n"
        }
      ]
    },
    {
      "section_name": "Company Information",
      "links": [
        {
          "title": "Management Team",
          "url": "https://lexariabioscience.com/investors/management-team/",
          "content": "Lexaria Bioscience - [![Lexaria Bioscience]( http://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB.png)](https://lexariabioscience.com/ \"Lexaria Bioscience\")\n\nNASDAQ:LEXX; NASDAQ WARRANT:LEXXW \n\n[Contact](https://lexariabioscience.com/contact/)\n\n#  Management Team\n\n[Lexaria Bioscience](https://lexariabioscience.com \"Go to Lexaria Bioscience.\") → [Investor Relations](https://lexariabioscience.com/investors/ \"Go to Investor Relations.\") → Management Team\n\n☰\n\n  * [Overview](https://lexariabioscience.com/investors/)\n  * [Press Releases](https://lexariabioscience.com/investors/press-releases/)\n  * [Events & Presentations](https://lexariabioscience.com/investors/events-and-presentations/)\n  * [Company Info](https://lexariabioscience.com/investors/company-information/)\n    * [Overview](https://lexariabioscience.com/investors/company-information/)\n    * [Management Team](https://lexariabioscience.com/investors/management-team/)\n    * [Annual Meeting / Special Meeting](https://lexariabioscience.com/investors/meeting/)\n  * [Analyst Coverage](https://lexariabioscience.com/investors/analyst-coverage/)\n  * [Stock Data](https://lexariabioscience.com/investors/stock-data/)\n  * [Financial Info](https://lexariabioscience.com/investors/financial-information/)\n    * [SEC Filings](https://lexariabioscience.com/investors/sec-filings/)\n    * [Quarterly Reports](https://lexariabioscience.com/investors/quarterly-reports/)\n    * [SEDAR+](https://www.sedarplus.ca/landingpage/)\n  * [Legend Removal](https://lexariabioscience.com/investors/legend-removal/)\n  * [Governance](#)\n    * [Board of Directors](https://lexariabioscience.com/investors/board-of-directors/)\n    * [Governance Documents](https://lexariabioscience.com/investors/governance-documents/)\n    * [Board Committees](https://lexariabioscience.com/investors/board-committees/)\n  * [Resources](#)\n    * [Email Alerts](https://lexariabioscience.com/investors/email-alerts/)\n    * [Investor FAQ](https://lexariabioscience.com/investors/ir-faq/)\n    * [IR Contact](https://lexariabioscience.com/investors/ir-contact/)\n\n\n\n## Management Team\n\n### Management Team\n\n![Richard Christopher](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/RCC_Headshot_GJ__NEW.png)\n\n[Richard Christopher](4639)\n\nCEO\n\nX\n\n![Richard Christopher](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/RCC_Headshot_GJ__NEW.png)\n\nRichard Christopher\n\nCEO\n\nMr. Christopher was the Chief Financial Officer at InVivo Therapeutics, a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries. Prior to joining InVivo, Mr. Christopher was the Chief Financial Officer of iCAD, Inc., a company with a focus on therapies and solutions for the early identification and treatment of cancer, where he held both financial and operational responsibilities. Before joining iCAD, Mr. Christopher was Chief Financial Officer and Chief Operating Officer of Caliber Imaging & Diagnostics, Inc., a medical technology company focused on cancer detection imaging solutions, with primary applications in dermatology. Preceding Caliber, Mr. Christopher held various positions of increasing responsibility at DUSA Pharmaceuticals, Inc., a dermatology company focused on the treatment of precancerous skin lesions. He was with DUSA for a period of 12.5 years, where he ultimately served as Chief Financial Officer for 8.5 years before the company’s acquisition and integration into Sun Pharmaceuticals Industries Ltd. Mr. Christopher holds a Master of Science in Accounting from Suffolk University and a Bachelor of Science in Finance from Bentley University.\n\n![John Docherty](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/John-Docherty-1.jpg)\n\n[John Docherty](4601)\n\nPresident and Director\n\nX\n\n![John Docherty](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/John-Docherty-1.jpg)\n\nJohn Docherty\n\nPresident and Director\n\nJohn became President of Lexaria in the Spring of 2015 and joined its board of directors a year later. Mr. Docherty was former President and Chief Operating officer of Helix BioPharma Corp. (TSX: HBP), where he led the company’s pharmaceutical development programs for its plant and recombinantly derived therapeutic protein product candidates.Mr. Docherty is a senior operations and management executive with over 20 years of experience in the pharmaceutical and biopharmaceutical sectors. He has worked with large multinational companies, as well as emerging private and publicly-traded start-ups. At Helix, Mr. Docherty was also instrumental in the areas of investor and stakeholder relations, capital raising, capital markets development, strategic partnering, regulatory authority interactions and media relations, and he also served as a management member of its board of directors. Prior to this, Mr. Docherty was president and a board member of PharmaDerm Laboratories Ltd., a Canadian drug delivery company that developed unique microencapsulation formulation technologies for use with a range of active compounds.Mr. Docherty has also held positions with companies such as Astra Pharma Inc., Nu-Pharm Inc. and PriceWaterhouseCoopers’ former global pharmaceutical industry consulting practice. He is a named inventor on issued and pending patents and he has a M.Sc. in Pharmacology and a B.Sc. in Toxicology from the University of Toronto.\n\n![Michael Shankman, CPA](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/Michael-Shankman-2.jpg)\n\n[Michael Shankman, CPA](4699)\n\nCFO\n\nX\n\n![Michael Shankman, CPA](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/Michael-Shankman-2.jpg)\n\nMichael Shankman, CPA\n\nCFO\n\nMr. Shankman has previously worked with Lexaria and assisted with its financial reporting and 2023 audit as a designated contractor and as such is deeply familiar with the Company. From 2021 to 2024 Mr. Shankman provided outsourced CFO and Controller services for a national service provider, gaining extensive experience and familiarity with both public and private companies in a wide variety of industry fields. Previously, Mr. Shankman held financial leadership positions with increasing responsibility in a variety of industries, including biotechnology, medical devices, and software as service\n\n### Advisors\n\n![Chris Bunka](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/Chris-Bunka-1.jpg)\n\n[Chris Bunka](4600)\n\nChairman of the Board, Executive Strategic Advisor\n\nX\n\n![Chris Bunka](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/Chris-Bunka-1.jpg)\n\nChris Bunka\n\nChairman of the Board, Executive Strategic Advisor\n\nChris was the former CEO of Lexaria and has been Chairman of the Board since 2006 and was primarily responsible for the corporate pivot from older business activities to bioscience. Chris is a serial entrepreneur and has been involved in several private and public companies since the late 1980's. He was well known for more than a decade as a part-time business commentator in print and radio, as well as an author. He has extensive experience in the capital markets, corporate governance, project acquisition and corporate finance. He is a named inventor on some of Lexaria's pending patents.\n\n![Julian Gangolli](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/Julian.png)\n\n[Julian Gangolli](4641)\n\nStrategic Advisor\n\nX\n\n![Julian Gangolli](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/Julian.png)\n\nJulian Gangolli\n\nStrategic Advisor\n\nJulian Gangolli is a proven and respected senior executive with a visible and successful track record at highly regarded publicly traded companies. He joined Allergan in 1998 and was North American President when it was sold in 2015, after becoming one of the leading specialty pharmaceutical companies in the United States.Mr. Gangolli joined GW Pharmaceuticals in 2015 as US President. As President he oversaw the approval of the first CBD drug by the FDA and the subsequent successful commercialization of Epidiolex® in the US. Epidiolex® is indicated for the treatment of refractory epilepsies and seizures in children. The commercial success of Epidiolex® in the US led to the acquisition of GW Pharmaceuticals by Jazz Pharmaceuticals in 2021 for over $7 billion.\n\n![Dr. Philip Ainslie](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/PHILIP-1.jpg)\n\n[Dr. Philip Ainslie](4640)\n\nAdvisor & Consultant\n\nX\n\n![Dr. Philip Ainslie](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/PHILIP-1.jpg)\n\nDr. Philip Ainslie\n\nAdvisor & Consultant\n\nDr. Ainslie is Co-Director for the Centre for Heart, Lung and Vascular Health, Canada, Research Chair in Cerebrovascular Physiology and Professor, School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia, Okanagan Campus. His research is directed to the integrated mechanisms, which regulate human cerebral blood flow in health and disease with specific areas of interest including fundamental mechanisms of cerebral blood flow regulation, influence of environmental stress on cerebrovascular function (with focus on normobaric and hypobaric hypoxia; in addition to temperature regulation and influence of different forms of sleep apnea on cerebrovascular function).\n\n[](#top)\n"
        },
        {
          "title": "Board of Directors",
          "url": "https://lexariabioscience.com/investors/board-of-directors/",
          "content": "Lexaria Bioscience - [![Lexaria Bioscience]( http://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB.png)](https://lexariabioscience.com/ \"Lexaria Bioscience\")\n\nNASDAQ:LEXX; NASDAQ WARRANT:LEXXW \n\n[Contact](https://lexariabioscience.com/contact/)\n\n#  Board of Directors\n\n[Lexaria Bioscience](https://lexariabioscience.com \"Go to Lexaria Bioscience.\") → [Investor Relations](https://lexariabioscience.com/investors/ \"Go to Investor Relations.\") → Board of Directors\n\n☰\n\n  * [Overview](https://lexariabioscience.com/investors/)\n  * [Press Releases](https://lexariabioscience.com/investors/press-releases/)\n  * [Events & Presentations](https://lexariabioscience.com/investors/events-and-presentations/)\n  * [Company Info](https://lexariabioscience.com/investors/company-information/)\n    * [Overview](https://lexariabioscience.com/investors/company-information/)\n    * [Management Team](https://lexariabioscience.com/investors/management-team/)\n    * [Annual Meeting / Special Meeting](https://lexariabioscience.com/investors/meeting/)\n  * [Analyst Coverage](https://lexariabioscience.com/investors/analyst-coverage/)\n  * [Stock Data](https://lexariabioscience.com/investors/stock-data/)\n  * [Financial Info](https://lexariabioscience.com/investors/financial-information/)\n    * [SEC Filings](https://lexariabioscience.com/investors/sec-filings/)\n    * [Quarterly Reports](https://lexariabioscience.com/investors/quarterly-reports/)\n    * [SEDAR+](https://www.sedarplus.ca/landingpage/)\n  * [Legend Removal](https://lexariabioscience.com/investors/legend-removal/)\n  * [Governance](#)\n    * [Board of Directors](https://lexariabioscience.com/investors/board-of-directors/)\n    * [Governance Documents](https://lexariabioscience.com/investors/governance-documents/)\n    * [Board Committees](https://lexariabioscience.com/investors/board-committees/)\n  * [Resources](#)\n    * [Email Alerts](https://lexariabioscience.com/investors/email-alerts/)\n    * [Investor FAQ](https://lexariabioscience.com/investors/ir-faq/)\n    * [IR Contact](https://lexariabioscience.com/investors/ir-contact/)\n\n\n\n## Board of Directors\n\n![Chris Bunka](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/Chris-Bunka-1.jpg)\n\n[Chris Bunka](4600)\n\nChairman of the Board, Executive Strategic Advisor\n\nX\n\n![Chris Bunka](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/Chris-Bunka-1.jpg)\n\nChris Bunka\n\nChairman of the Board, Executive Strategic Advisor\n\nChris was the former CEO of Lexaria and has been Chairman of the Board since 2006 and was primarily responsible for the corporate pivot from older business activities to bioscience. Chris is a serial entrepreneur and has been involved in several private and public companies since the late 1980's. He was well known for more than a decade as a part-time business commentator in print and radio, as well as an author. He has extensive experience in the capital markets, corporate governance, project acquisition and corporate finance. He is a named inventor on some of Lexaria's pending patents.\n\n![John Docherty](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/John-Docherty-1.jpg)\n\n[John Docherty](4601)\n\nPresident and Director\n\nX\n\n![John Docherty](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/John-Docherty-1.jpg)\n\nJohn Docherty\n\nPresident and Director\n\nJohn became President of Lexaria in the Spring of 2015 and joined its board of directors a year later. Mr. Docherty was former President and Chief Operating officer of Helix BioPharma Corp. (TSX: HBP), where he led the company’s pharmaceutical development programs for its plant and recombinantly derived therapeutic protein product candidates.Mr. Docherty is a senior operations and management executive with over 20 years of experience in the pharmaceutical and biopharmaceutical sectors. He has worked with large multinational companies, as well as emerging private and publicly-traded start-ups. At Helix, Mr. Docherty was also instrumental in the areas of investor and stakeholder relations, capital raising, capital markets development, strategic partnering, regulatory authority interactions and media relations, and he also served as a management member of its board of directors. Prior to this, Mr. Docherty was president and a board member of PharmaDerm Laboratories Ltd., a Canadian drug delivery company that developed unique microencapsulation formulation technologies for use with a range of active compounds.Mr. Docherty has also held positions with companies such as Astra Pharma Inc., Nu-Pharm Inc. and PriceWaterhouseCoopers’ former global pharmaceutical industry consulting practice. He is a named inventor on issued and pending patents and he has a M.Sc. in Pharmacology and a B.Sc. in Toxicology from the University of Toronto.\n\n![Nicholas Baxter](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/Nicholas-Baxter-1.jpg)\n\n[Nicholas Baxter](4602)\n\nDirector\n\nX\n\n![Nicholas Baxter](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/Nicholas-Baxter-1.jpg)\n\nNicholas Baxter\n\nDirector\n\nNick was appointed as a member on the board of directors of Lexaria Corp. in 2009. Nick received a Bachelor of Science (Honours) from the University of Liverpool in 1975, and has worked on oil & gas projects in many areas of the world. Since the 1980’s, he has worked with companies in the public markets both in the U.K. and in Canada. Nick brings extensive real-world experience as a board member.\n\n![Ted McKechnie](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/Ted-McKechnie-1.jpg)\n\n[Ted McKechnie](4603)\n\nDirector\n\nX\n\n![Ted McKechnie](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/Ted-McKechnie-1.jpg)\n\nTed McKechnie\n\nDirector\n\nTed is a well-recognized thought leader in the Canadian food industry. In the past, Ted was president of Maple Leaf Foods, an owner and senior executive at Humpty Dumpty and a senior leader at Pepsi Co. After a distinguished career as an executive and marketer specializing in food manufacturing, he now focuses on moving the Canadian food sector into the future. Besides being the chairman of Food Starter’s board, Ted is also the Chairman/CEO of The Davies Group and William Davies Consulting Inc. Ted is also a chairman of the board for Advanced Technology For Food Manufacturing, and the Director of Lexaria Bioscience Corporation.Ted is often called upon by think tanks, the government and industry leaders to offer insights on how to grow the food sector and add more value to the Canadian economy.\n\n![Al Reese](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/Al-Reese-1.jpg)\n\n[Al Reese](4604)\n\nDirector\n\nX\n\n![Al Reese](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/Al-Reese-1.jpg)\n\nAl Reese\n\nDirector\n\nMr. Reese has over 40 years experience in public and private businesses and has served in board positions for energy companies and commercial banks. He was the Chief Financial Officer of a multi-billion dollar public energy company and has directed over 50 acquisitions and financings ranging in size from several hundred thousand dollars to multibillion dollars. He served as CFO of ATP Oil and Gas from 1999 until 2014 during which time he guided ATP in equity, debt, and mezzanine transaction totaling over $10 billion. Mr. Reese received his Bachelor’s Degree in Business Administration (Finance) from Texas A&M University in 1971 and his Master of Business Administration from University of Houston in 1977, and is a Certified Public Accountant.\n\n![Dr. Catherine Turkel, PharmD, PhD](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/CATHERINE-TURKEL-1.jpg)\n\n[Dr. Catherine Turkel, PharmD, PhD](4605)\n\nDirector\n\nX\n\n![Dr. Catherine Turkel, PharmD, PhD](https://s3.amazonaws.com/b2iweb.irpass.cc/2978/CATHERINE-TURKEL-1.jpg)\n\nDr. Catherine Turkel, PharmD, PhD\n\nDirector\n\nDr. Turkel has more than 20 years' experience as an executive in start-up and mid-size pharma/biotech companies. She was Founder and CEO of Nezee Therapeutics and served as President and R&D head at Novus Therapeutics (renamed Eledon Pharmaceuticals - Nasdaq: ELDN). She currently acts as an independent Board Director at Object Pharma (private) and Prostate Cancer Research (nonprofit; member of the Translational Scientific Advisory Committee) and is a Dean Advisor at Chapman University School of Pharmacy.Dr. Turkel has formulated Food and Drug Administration registration & commercial strategic plans and has led global development programs for pharmaceutical and biologic treatments from phase 1 through phase 4 related to Neurosciences, Pain, Cardiovascular, Psychiatry, Rare Diseases, Ophthalmology, Aesthetics, Urology and Otology therapeutic areas. Dr. Turkel designed and led Allergan's (now AbbVie - NYSE: ABBV) pioneering BOTOX® Chronic Migraine registration program, generating revenue of more than a billion dollars.\n\n[](#top)\n"
        }
      ]
    }
  ]
}